Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Looks To “Exploit” Switches With Exit From J&J Joint Venture

This article was originally published in The Tan Sheet

Executive Summary

Merck gains flexibility to pursue Rx-to-OTC switches, such as allergy drug Clarinex and cholesterol treatment Zetia by exiting its OTC joint venture with Johnson & Johnson.
Advertisement

Related Content

J&J Brand Revival Plan Relies On Marketing, Delivery Innovation
Asthma Treatment OTC Switches Would Face Tough Barriers
J&J’s Caruso Pitches OTC Comeback To Analysts
Issa Scolds FDA On Failure To Inspect McNeil Plant
Perrigo Banks On Product Launches, OTC Switches For "Significant Growth"
Perrigo Banks On Product Launches, OTC Switches For "Significant Growth"
FDA Questions J&J/Merck OTC Joint Venture's Manufacturing Practices
Merck Gives Consumer Health Care Division Direct Line To CEO
Switch Projected To Continue Driving OTC Market Growth In 5-Year Picture
Schering-Plough Merger Offers Merck OTC Business, Zegerid Switch Rights
Advertisement
UsernamePublicRestriction

Register

PS105330

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel